^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    anzutresgene autoleucel (IMA203)

    i
    Other names: IMA203, autologous TCR-engineered T cells, ACTengine IMA203, IMA 2013, IMA203 T-cell product, IMA2013, IMA-2013, IMA-203, IMA 203, anzu-cel
    Associations

    News

    Trials
    Company:
    Immatics
    Drug class:
    PRAME inhibitor
    Related drugs:
    Associations

    News

    Trials
    19h
    SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (clinicaltrials.gov)
    P3, N=360, Recruiting, Immatics US, Inc. | N=96 --> 360
    Enrollment change
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab) • carboplatin • temozolomide • albumin-bound paclitaxel • cyclophosphamide • dacarbazine • Amtagvi (lifileucel) • relatlimab (BMS-986016) • anzutresgene autoleucel (IMA203)
    7d
    SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (clinicaltrials.gov)
    P3, N=96, Recruiting, Immatics US, Inc.
    New P3 trial
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab) • carboplatin • temozolomide • albumin-bound paclitaxel • cyclophosphamide • dacarbazine • Amtagvi (lifileucel) • relatlimab (BMS-986016) • anzutresgene autoleucel (IMA203)
    8ms
    ACTengine® IMA203 Combined With mRNA-4203 (clinicaltrials.gov)
    P1, N=15, Recruiting, Immatics US, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • fludarabine IV • anzutresgene autoleucel (IMA203)
    8ms
    ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (clinicaltrials.gov)
    P1/2, N=375, Recruiting, Immatics US, Inc. | Phase classification: P1 --> P1/2 | Trial completion date: Dec 2028 --> Jun 2032
    Phase classification • Trial completion date
    |
    Opdivo (nivolumab) • IMA203CD8 • anzutresgene autoleucel (IMA203)
    9ms
    ACTengine® IMA203 Combined With mRNA-4203 (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, Immatics US, Inc. | Initiation date: May 2025 --> Aug 2025
    Trial initiation date
    |
    cyclophosphamide • fludarabine IV • anzutresgene autoleucel (IMA203)
    12ms
    ACTengine® IMA203 Combined With mRNA-4203 (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, Immatics US, Inc.
    New P1 trial
    |
    cyclophosphamide • fludarabine IV • anzutresgene autoleucel (IMA203)
    1year
    Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial. (PubMed, Nat Med)
    Overall, IMA203 showed promising anti-tumor activity in multiple solid tumors, including refractory melanoma. ClinicalTrials.gov identifier: NCT03686124 .
    P1 data • Journal • IO biomarker
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • PRAME (Preferentially Expressed Antigen In Melanoma)
    |
    anzutresgene autoleucel (IMA203)
    over1year
    SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (clinicaltrials.gov)
    P3, N=360, Recruiting, Immatics US, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab) • carboplatin • temozolomide • albumin-bound paclitaxel • cyclophosphamide • dacarbazine • Amtagvi (lifileucel) • relatlimab (BMS-986016) • anzutresgene autoleucel (IMA203)
    over1year
    SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (clinicaltrials.gov)
    P3, N=360, Not yet recruiting, Immatics US, Inc.
    New P3 trial
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab) • carboplatin • temozolomide • albumin-bound paclitaxel • cyclophosphamide • dacarbazine • Amtagvi (lifileucel) • relatlimab (BMS-986016) • anzutresgene autoleucel (IMA203)
    over1year
    ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (clinicaltrials.gov)
    P1, N=476, Recruiting, Immatics US, Inc. | N=186 --> 476
    Enrollment change
    |
    Opdivo (nivolumab) • IMA203CD8 • anzutresgene autoleucel (IMA203)